Comparing Palliative Radiotherapy With or Without Carboplatin

The study population has locally advanced or metastatic bronchial or head and neck cancer. This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during metastatic radiotherapy versus radiotherapy alone. The realization of a systemic treatment during the radiotherapy could make it possible to obtain a benefit on the control of the evolution of the metastases and thus of the pains generated, as well as on the quality of life of the patients. In addition, a benefit in overall survival is possible.

Inclusion Criteria: * Patients with locally advanced or metastatic bronchial or head and neck cancer * Patient require palliative radiotherapy * Age ≥ 18 years * PS ≤ 2 * Obtaining the signed written consent of the patient * Patient affiliated to a social security scheme Exclusion Criteria: * Other chemotherapy or targeted therapy * Prior radiation * Patients with thrombopenia \< 100 000 * Patients with neutropenia \< 2000 * Patients with renal clearance \< 20 mL/min * Known hypersensitivity to platinum salt * Treatment with phenytoin or fosphenytoin * In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine * Unchecked diabetes * hemorrhagic tumor * Refusal of participation or inability to issue informed consent * Person deprived of liberty or adult under guardianship * Minor patients, pregnant or lactating women * Participation in other interventional study